U.S. Markets closed

Illumina Stock Is Plummeting but Analysts Still Favor Genome Company

Josh Nathan-Kazis

Illumina, the company that makes the machines that fuel the current boom in personal genome sequencing, disclosed preliminary revenue figures on Thursday evening that fell well short of its own estimates, sending shares down 14% in premarket trading on Friday.